Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-C0902 in Advanced Solid Tumors
NCT07181681Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of BG-C0902 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 24 months, Number of Participants with Dose Limiting Toxicities at 21 days and 4 more. Started Nov 2025; status: recruiting.
02
Drugs
BG-C0902
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07181681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181681.